Several companies have submitted their unaudited financial results for the third quarter of FY26, covering the period ended December 31, 2025, in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Astal Laboratories Limited Performance

Astal Laboratories Limited reported strong operational performance for Q3 FY26. The company's financial results were approved by the Board of Directors at their meeting held on February 14, 2026.

Coromandel Agro Products and Oils Limited Results

Coromandel Agro Products and Oils Limited, registered in Andhra Pradesh, reported its quarterly performance with total income from operations reaching ₹2,708.80 lakhs for Q3 FY26.

Objective Information Systems Limited Performance

Objective Information Systems Limited, operating in the IT/ITES segment, submitted its unaudited results showing total income from operations of ₹392.58 lakhs for the quarter.

Regulatory Compliance and Publication

All companies have published their financial results in leading newspapers including The Financial Express, The Business Standard, and The Jansatta as required under Regulation 47 of the SEBI regulations. The results have also been made available on respective company websites and BSE's official portal for investor access.

Business Operations Overview

Astal Laboratories operates in manufacturing and trading of active pharmaceutical ingredients, while Coromandel Agro Products focuses on agro-based products and oils. Objective Information Systems operates primarily in the IT services sector. All companies have prepared their financial results in accordance with Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013.

Astal Laboratories Limited has announced a substantial equity investment through the allotment of 29,56,666 shares to non-promoter investors under a preferential allotment arrangement. The transaction, completed on January 14, 2026, represents a significant capital infusion for the pharmaceutical company.

Share Allotment Details

The preferential allotment was made to two non-promoter investors through a share swap mechanism. The distribution of shares and their impact on shareholding is detailed below:

Both investors previously held zero shares in the company, making this their initial investment in Astal Laboratories. The allotment was made pursuant to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Capital Structure Transformation

The preferential allotment has significantly altered the company's capital structure. The equity share capital witnessed substantial growth following this transaction:

The transaction represents an investment of approximately ₹29.57 crores based on the face value of ₹10 per share, demonstrating significant investor confidence in the company's prospects.

Regulatory Compliance

Astal Laboratories has fulfilled all regulatory requirements under SEBI regulations. The company submitted the necessary disclosures to BSE Limited on January 19, 2026, through Company Secretary Mahendra Kumar. The disclosure was made in the prescribed format under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The share swap arrangement facilitated this preferential allotment, indicating a strategic transaction rather than a cash-based investment. This method of capital raising suggests potential synergies or strategic partnerships between the parties involved.

Company Profile

Astal Laboratories Limited, formerly known as Macro International Limited, operates from its registered office in Noida, Uttar Pradesh, with corporate offices in Telangana. The company trades on BSE Limited under scrip code 512600 with the security ID ASTALLTD. The pharmaceutical company has been incorporated since 1993 and maintains its focus on laboratory and pharmaceutical operations.